Written by
November 20, 2012

FDA Accepts Orexo’s Zubsolv for Review

Sweden’s Orexo has revealed that the US Food and Drug Administration (FDA) have accepted the New Drug Application (NDA) for their opioid dependence drug, Zubsolv, for review. Zubsolv is a sublingual formulation of Reckitt Benckiser’s Suboxone which governs a market that is predicted to reach sales of $1.5 billion in 2012 and continues to exhibit

Continue Reading

Written by
February 1, 2012

Johnson & Johnson Terminate Agreements with Orexo

Sweden’s Orexo suffered a major setback yesterday after the announcement that Johnson & Johnson had decided to end the firms’ anti-inflammatory collaboration. The agreement with the healthcare company’s Janssen Pharmaceuticals unit aligned around two research projects in the arachidonic acid field. The OX-CLI and OX‑ESI programmes were concentrated on developing treatments for asthma, chronic obstructive

Continue Reading